These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 33951415)

  • 21. Impact of PCSK9 inhibitors on coronary atheroma phenotype following myocardial infarction: insights from intravascular imaging.
    Abrahams T; Fujino M; Nelson AJ; Nicholls SJ
    Curr Opin Cardiol; 2023 Nov; 38(6):504-508. PubMed ID: 37751373
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of routine early treatment with PCSK9 inhibitors in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: a randomised, double-blind, sham-controlled trial.
    Mehta SR; Pare G; Lonn EM; Jolly SS; Natarajan MK; Pinilla-Echeverri N; Schwalm JD; Sheth TN; Sibbald M; Tsang M; Valettas N; Velianou JL; Lee SF; Ferdous T; Nauman S; Nguyen H; McCready T; McQueen MJ
    EuroIntervention; 2022 Dec; 18(11):e888-e896. PubMed ID: 36349701
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the Impact of Colchicine on Coronary Plaque Phenotype After Myocardial Infarction with Optical Coherence Tomography: Rationale and Design of the COCOMO-ACS Study.
    Montarello NJ; Singh K; Sinhal A; Wong DTL; Alcock R; Rajendran S; Dautov R; Barlis P; Patel S; Nidorf SM; Thompson PL; Salagaras T; Butters J; Nerlekar N; Di Giovanni G; Ottaway JL; Nicholls SJ; Psaltis PJ
    Cardiovasc Drugs Ther; 2022 Dec; 36(6):1175-1186. PubMed ID: 34432196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Alirocumab and Coronary Atherosclerosis in Asymptomatic Patients with Familial Hypercholesterolemia: The ARCHITECT Study.
    Pérez de Isla L; Díaz-Díaz JL; Romero MJ; Muñiz-Grijalvo O; Mediavilla JD; Argüeso R; Sánchez Muñoz-Torrero JF; Rubio P; Álvarez-Baños P; Ponte P; Mañas D; Suárez Gutierrez L; Cepeda JM; Casañas M; Fuentes F; Guijarro C; Ángel Barba M; Saltijeral Cerezo A; Padró T; Mata P;
    Circulation; 2023 May; 147(19):1436-1443. PubMed ID: 37009731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy.
    Koskinas KC; Zaugg S; Yamaji K; García-García HM; Taniwaki M; Klingenberg R; Moschovitis A; Lüscher TF; van Tits LJ; Matter CM; Windecker S; Räber L
    Atherosclerosis; 2016 Apr; 247():154-60. PubMed ID: 26921743
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
    Kereiakes DJ; Lepor NE; Gerber R; Veronica Lee L; Elassal J; Thompson D; Michael Gibson C
    Atherosclerosis; 2018 Oct; 277():211-218. PubMed ID: 30025648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial.
    Nissen SE; Nicholls SJ; Sipahi I; Libby P; Raichlen JS; Ballantyne CM; Davignon J; Erbel R; Fruchart JC; Tardif JC; Schoenhagen P; Crowe T; Cain V; Wolski K; Goormastic M; Tuzcu EM;
    JAMA; 2006 Apr; 295(13):1556-65. PubMed ID: 16533939
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Factors underlying regression of coronary atheroma with potent statin therapy.
    Puri R; Nissen SE; Ballantyne CM; Barter PJ; Chapman MJ; Erbel R; Libby P; Raichlen JS; St John J; Wolski K; Uno K; Kataoka Y; Nicholls SJ
    Eur Heart J; 2013 Jun; 34(24):1818-25. PubMed ID: 23644179
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale.
    Teramoto T; Kondo A; Kiyosue A; Harada-Shiba M; Ishigaki Y; Tobita K; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    Lipids Health Dis; 2017 Jun; 16(1):121. PubMed ID: 28623954
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
    Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
    Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of alirocumab 150mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON.
    Teramoto T; Kiyosue A; Ishigaki Y; Harada-Shiba M; Kawabata Y; Ozaki A; Baccara-Dinet MT; Sata M
    J Cardiol; 2019 Mar; 73(3):218-227. PubMed ID: 30509509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo relationship between near-infrared spectroscopy-detected lipid-rich plaques and morphological plaque characteristics by optical coherence tomography and intravascular ultrasound: a multimodality intravascular imaging study.
    Zanchin C; Ueki Y; Losdat S; Fahrni G; Daemen J; Ondracek AS; Häner JD; Stortecky S; Otsuka T; Siontis GCM; Rigamonti F; Radu M; Spirk D; Kaiser C; Engstrom T; Lang I; Koskinas KC; Räber L
    Eur Heart J Cardiovasc Imaging; 2021 Jun; 22(7):824-834. PubMed ID: 31990323
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of statin therapy on plaque characteristics as assessed by serial OCT, grayscale and integrated backscatter-IVUS.
    Hattori K; Ozaki Y; Ismail TF; Okumura M; Naruse H; Kan S; Ishikawa M; Kawai T; Ohta M; Kawai H; Hashimoto T; Takagi Y; Ishii J; Serruys PW; Narula J
    JACC Cardiovasc Imaging; 2012 Feb; 5(2):169-77. PubMed ID: 22340823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of Evolocumab on Coronary Plaque Composition.
    Nicholls SJ; Puri R; Anderson T; Ballantyne CM; Cho L; Kastelein JJP; Koenig W; Somaratne R; Kassahun H; Yang J; Wasserman SM; Honda S; Shishikura D; Scherer DJ; Borgman M; Brennan DM; Wolski K; Nissen SE
    J Am Coll Cardiol; 2018 Oct; 72(17):2012-2021. PubMed ID: 30336824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction.
    Schwartz GG; Giugliano RP
    Curr Opin Lipidol; 2022 Jun; 33(3):147-159. PubMed ID: 35695614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical impact of PCSK9 inhibitor on stabilization and regression of lipid-rich coronary plaques: a near-infrared spectroscopy study.
    Ota H; Omori H; Kawasaki M; Hirakawa A; Matsuo H
    Eur Heart J Cardiovasc Imaging; 2022 Jan; 23(2):217-228. PubMed ID: 33637979
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between Low-Density Lipoprotein Cholesterol, Free Proprotein Convertase Subtilisin/Kexin Type 9, and Alirocumab Levels After Different Lipid-Lowering Strategies.
    Rey J; Poitiers F; Paehler T; Brunet A; DiCioccio AT; Cannon CP; Surks HK; Pinquier JL; Hanotin C; Sasiela WJ
    J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27287699
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intensity of statin treatment after acute coronary syndrome, residual risk, and its modification by alirocumab: insights from the ODYSSEY OUTCOMES trial.
    Diaz R; Li QH; Bhatt DL; Bittner VA; Baccara-Dinet MT; Goodman SG; Jukema JW; Kimura T; Parkhomenko A; Pordy R; Reiner Ž; Roe MT; Szarek M; Tse HF; White HD; Zahger D; Zeiher AM; Schwartz GG; Steg PG;
    Eur J Prev Cardiol; 2021 Mar; 28(1):33-43. PubMed ID: 33755145
    [TBL] [Abstract][Full Text] [Related]  

  • 39. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
    Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
    J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography.
    Auscher S; Heinsen L; Nieman K; Vinther KH; Løgstrup B; Møller JE; Broersen A; Kitslaar P; Lambrechtsen J; Egstrup K
    Atherosclerosis; 2015 Aug; 241(2):579-87. PubMed ID: 26115069
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.